Pediatric SJS/TEN Subdued by a Combination of Dexamethasone, Cyclosporine, and Etanercept.

Jerome CoulombeEugénie BelzileAmélie DuhamelPauline RaultChantal ButeauJean-Jacques DeBruyckerJean-François Bussières

Published in: Journal of cutaneous medicine and surgery (2020)

We report a case of an 17-year-old male with a drug reaction in the spectrum of Stevens-Johnson syndrome (SJS)/toxic epidermal necrolysis (TEN), triggered by carbamazepine, who was succesfully treated with the combination of dexamethasone, cyclosporine, and etanercept. This triple therapy halted and prevented skin epidermolysis without immediate or late onset complications.

Keyphrases

late onset
rheumatoid arthritis
early onset
ankylosing spondylitis
rheumatoid arthritis patients
juvenile idiopathic arthritis
high dose
low dose
wound healing
disease activity
risk factors
soft tissue
stem cells
case report
emergency department
newly diagnosed
young adults
replacement therapy
childhood cancer